Multivariate analysis: thyroid dysfunction
| Variable . | No. patients . | Percentage abnormal* . | HR (95% CI) . | P . | Overall P . |
|---|---|---|---|---|---|
| Regimen | |||||
| CY + TBI† | 538 | 32 | 1.0 | ||
| BUCY/BU MELTT | 108 | 23 | 0.84 (0.5-1.4) | .48 | |
| BU + TBI‡ | 61 | 56 | 1.7 (1.1-2.5) | .009 | |
| CY | 84 | 7 | 0.32 (0.1-0.9) | .03 | .008 |
| Local radiotherapy | |||||
| No | 761 | 29 | 1.0 | ||
| Yes§ | 30 | 57 | 1.82 (1.0-3.2) | .05 | .05 |
| Age at HCT, y | |||||
| 10 or more | 372 | 25 | 1/0 | ||
| 0-9 | 419 | 35 | 1.7 (1.3-2.2) | .001 | <.001 |
| Diagnosis | |||||
| Nonmalignant | 160 | 11 | 1.0 | ||
| Myeloid | 314 | 35 | 2.92 (1.5-5.8) | .002 | |
| Lymphoid | 302 | 33 | 2.86 (1.4-5.8) | .004 | |
| Hodgkin | 15 | 73 | 15 (5.8-38) | <.001 | <.001 |
| Variable . | No. patients . | Percentage abnormal* . | HR (95% CI) . | P . | Overall P . |
|---|---|---|---|---|---|
| Regimen | |||||
| CY + TBI† | 538 | 32 | 1.0 | ||
| BUCY/BU MELTT | 108 | 23 | 0.84 (0.5-1.4) | .48 | |
| BU + TBI‡ | 61 | 56 | 1.7 (1.1-2.5) | .009 | |
| CY | 84 | 7 | 0.32 (0.1-0.9) | .03 | .008 |
| Local radiotherapy | |||||
| No | 761 | 29 | 1.0 | ||
| Yes§ | 30 | 57 | 1.82 (1.0-3.2) | .05 | .05 |
| Age at HCT, y | |||||
| 10 or more | 372 | 25 | 1/0 | ||
| 0-9 | 419 | 35 | 1.7 (1.3-2.2) | .001 | <.001 |
| Diagnosis | |||||
| Nonmalignant | 160 | 11 | 1.0 | ||
| Myeloid | 314 | 35 | 2.92 (1.5-5.8) | .002 | |
| Lymphoid | 302 | 33 | 2.86 (1.4-5.8) | .004 | |
| Hodgkin | 15 | 73 | 15 (5.8-38) | <.001 | <.001 |
CI indicates confidence interval; TBI, total body irradiation; BU, busulfan; CY, cyclophosphamide; MEL, melphlan; TT, thiotepa; and HCT, hematopoietic cell transplantation.
Percent of patients with abnormal thyroid function.
Cyclophosphamide with or without other chemotherapy agents.
Includes 18 BUCY + TBI patients, 3 BU + TBI, 40 BUCY for HCT no. 1, and CY/TBI for HCT no. 2.
Local radiotherapy included spinal, mantle, and total lymphoid irradiation.